High-Dose Radiation Doubles Survival for Large Liver Bile Duct Tumors, Study Finds
A study conducted by researchers at The University of Texas MD Anderson Cancer Center indicates that a specialized high-dose radiation delivery method may improve outcomes for patients with large intrahepatic cholangiocarcinoma, a type of bile duct tumor located in the liver.
The retrospective study found that patients who received this radiation treatment in combination with chemotherapy experienced a median survival more than double that of patients treated with chemotherapy alone.
Groundbreaking Study Reveals Improved Outcomes
The study, published in Clinical Cancer Research, was led by Ethan Ludmir, M.D., and Eugene Koay, M.D., Ph.D., from Gastrointestinal Radiation Oncology. It focused on intrahepatic cholangiocarcinoma tumors, specifically those exceeding 10 centimeters, which are categorized as supermassive tumors.
Key findings from the study include:
- Overall Survival: For 34 patients treated with ablative radiation combined with chemotherapy, the median overall survival was 28.7 months. This compared to 11.9 months for 29 patients who received chemotherapy alone. The median follow-up for the study was 17.9 months.
- Liver Failure Rates: The combination treatment group demonstrated significantly lower rates of tumor-related liver failure, at 12.1%, compared to 47.1% in the chemotherapy-alone group.
- Comparative Data: These survival figures align with data from the National Cancer Database, which reported an overall survival of 11.6 months for qualifying patients treated with chemotherapy alone.
Researchers also conducted molecular and histological analyses, which indicated that these very large tumors were not biologically distinct from smaller ones. This finding supported the hypothesis that tumor size should not be a limiting factor for radiation therapy. Given the relative rarity of supermassive tumors, the researchers suggested this study provides significant evidence for the effectiveness of this treatment approach.
Overcoming Historical Barriers: Advancements in Treatment
Historically, treating very large intrahepatic cholangiocarcinoma tumors with radiation was often avoided due to several considerations:
- Safety Concerns: Delivering a sufficient radiation dose to supermassive tumors was previously believed to exceed the tolerance of healthy liver tissue.
- Proximity to Vital Organs: These tumors are frequently located near critical organs, such as the stomach or bowels, which could be damaged by high radiation doses.
- Biological Perceptions: There was a belief that supermassive tumors might be biologically different from smaller ones and therefore less responsive to radiation in terms of extending survival, even if local control was achieved.
Over the past 10 to 15 years, advancements in radiation delivery techniques have enabled advanced radiation centers, including UT MD Anderson, to precisely administer ablative radiation doses. This precision allows for the eradication of tumors while minimizing damage to surrounding healthy tissue, even in challenging anatomical locations. The study is described as the initial analysis of outcomes specifically for this ablative radiation technique in this patient population.
Tolerability and Adverse Effects
Ablative radiation therapy was reported as generally well tolerated during the study.
- No grade 4 or 5 adverse effects were reported, indicating a favorable safety profile.
- Nine patients (26.5%) experienced manageable grade 3 radiation-induced liver disease.
- Two patients had late-onset grade 3 gastrointestinal hemorrhage, which was subsequently treated.
- No other adverse effects above grade three were noted.
Abi Jaoude, M.D., was the first author of the study. Funding for the study was provided by the National Institutes of Health (P30 CA016672).